Related Experiment Video
Updated: Jun 13, 2026
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
Jonas N Søndergaard1, Ramin Nazarian, Qi Wang
1Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Abstract:
Blocking oncogenic signaling induced by the BRAFV600E mutation is a promising approach for melanoma treatment. We tested the anti-tumor effects of a specific inhibitor of Raf protein kinases, PLX4032/RG7204, in melanoma cell lines. PLX4032 decreased signaling through the MAPK pathway only in cell lines with the BRAFV600E mutation. Seven out of 10 BRAFV600E mutant cell lines displayed sensitivity based on cell viability assays and three were resistant at concentrations up to 10 muM. Among the sensitive cell lines, four were highly sensitive with IC50 values below 1 muM, and three were moderately sensitive with IC50 values between 1 and 10 muM. There was evidence of MAPK pathway inhibition and cell cycle arrest in both sensitive and resistant cell lines. Genomic analysis by sequencing, genotyping of close to 400 oncogeninc mutations by mass spectrometry, and SNP arrays demonstrated no major differences in BRAF locus amplification or in other oncogenic events between sensitive and resistant cell lines. However, metabolic tracer uptake studies demonstrated that sensitive cell lines had a more profound inhibition of FDG uptake upon exposure to PLX4032 than resistant cell lines. In conclusion, BRAFV600E mutant melanoma cell lines displayed a range of sensitivities to PLX4032 and metabolic imaging using PET probes can be used to assess sensitivity.
Insights
Targeting the BRAFV600E mutation with PLX4032 shows varied melanoma cell sensitivity. Metabolic imaging may predict treatment response to this targeted therapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- BRAFV600E mutation drives melanoma oncogenesis.
- Targeting this mutation with kinase inhibitors is a key therapeutic strategy.
Purpose of the Study:
- To evaluate the anti-tumor effects of PLX4032 (a Raf kinase inhibitor) on melanoma cell lines harboring the BRAFV600E mutation.
- To investigate the range of sensitivities and identify potential biomarkers for response.
Main Methods:
- Testing PLX4032 in BRAFV600E mutant melanoma cell lines.
- Assessing cell viability, MAPK pathway signaling, cell cycle arrest, and genomic alterations.
- Utilizing metabolic tracer uptake studies (e.g., FDG PET) to evaluate cellular response.
Main Results:
- PLX4032 inhibited the MAPK pathway and induced cell cycle arrest in sensitive and resistant cell lines.
- Seven of ten BRAFV600E mutant cell lines showed sensitivity to PLX4032, with varying degrees (IC50 < 1 muM to 1-10 muM).
- No significant genomic differences were found between sensitive and resistant lines; however, sensitive cells showed greater inhibition of metabolic tracer uptake.
Conclusions:
- Melanoma cell lines with the BRAFV600E mutation exhibit diverse sensitivities to PLX4032.
- Metabolic imaging, such as using PET probes, can serve as a tool to assess sensitivity to PLX4032 treatment.
